Evidence map›Paper›PMID 40852996›Full record

ArticlemSystems2025

Human fecal microbiota transplantation attenuates high dietary oxalate-induced renal calcium oxalate crystal depositions in rats via repairing

Yuhao Zhou, Min Lei, Weihong Cai, Zhenglin Chang, Lingyue An, Shike Zhang, Daqiang Wei, Renjie Jiao, Jie Gao, Yangzhi Xu and 6 more

Abstract read
In one paragraph

Article in mSystems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yuhao Zhou *Department of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Min Lei *Department of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Weihong Cai *Department of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Zhenglin ChangDepartment of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Lingyue AnDepartment of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0000-0003-1706-1742
Shike ZhangDepartment of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Daqiang WeiDepartment of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Renjie JiaoSino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong, China.
Jie GaoDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yangzhi XuDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Hui YangDepartment of Gastroenterology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Mingzhao ZhuKey Laboratory of Epigenetic Regulation and Intervention, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Jiabao CaoCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Shujue LiGuangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0000-0001-8871-9498
Xiaolu DuanGuangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0000-0001-7885-1487
Wenqi WuDepartment of Urology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0009-0006-7467-9409

Funding

National Natural Science Foundation of China 82070719National Natural Science Foundation of China 82270745National Natural Science Foundation of China 82270807Natural Science Foundation of Guangdong Province 2024A1515012699Plan on enhancing scientific research in GMU 2024SRP065the Key Discipline Project of Guangzhou Urology 010G220184
6 · The paper itself

Abstract

High dietary oxalate (HDOx) diet is a key factor in kidney stone formation, with gut microbiota playing a significant role. Although several studies have indicated that fecal microbiota transplantation from healthy animals can effectively reduce renal calcium oxalate (CaOx) depositions in rats, the gut microbiota composition between human and animal still remains different. This study aims to explore the effect and underlying mechanisms of healthy human-source fecal microbiota transplantation (hFMT) on CaOx crystal depositions, providing new evidence for its potential clinical application in hyperoxaluria and kidney stone treatment. First, fecal microbiota were screened and collected from healthy individuals and transplanted into rats fed with hydroxyproline. We found that hFMT effectively inhibited crystal depositions and kidney injury induced by HDOx diet, regardless of antibiotic pretreatment. Additionally, 16S rDNA sequencing of gut microbiota identified that hFMT treatment reversed HDOx-induced gut microbiota composition change, particularly restoring the abundance and ecological network of IMPORTANCE: This study investigated that healthy hFMT could serve as a novel strategy to inhibit kidney CaOx deposition induced by HDOx diet. By transplanting healthy human gut microbiota into HDOx rats, we found that hFMT significantly reduced CaOx crystal depositions and kidney damage. The treatment also restored the gut microbiota composition, particularly the abundance of

Indexed as

Calcium OxalateFecal Microbiota TransplantationGastrointestinal MicrobiomeKidney CalculiAnimalsHumansHyperoxaluriaKidneyMaleOxalatesRatsRats, Sprague-DawleyCalcium OxalateOxalatescalcium oxalate crystal depositionsgut microbiotahealthy human-sourced fecal microbiota transplantation (hFMT)intestinal barrier damage

Identifiers

PMID40852996
PMCPMC12455927

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.